Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Language
Year range
1.
Arq. bras. oftalmol ; 79(5): 330-332, Sept.-Oct. 2016. graf
Article in English | LILACS | ID: biblio-827977

ABSTRACT

ABSTRACT We present the case of a 31-year-old patient with toxic anterior segment syndrome (TASS) that developed after undergoing deep anterior lamellar keratoplasty (DALK). She had keratoconus, and despite wearing hard contact lenses for many years in the left eye, her vision had deteriorated; therefore, DALK was performed on this eye. The preoperative visual acuity (VA) was finger counting at 3 m. Routine DALK was performed using the "big-bubble" technique. The corneal entry incision was hydrated at the end of the surgery, which was terminated by air injection into the anterior chamber. On postoperative day 1, VA was at the level of hand movements, and the cornea was edematous. Topical high-dose dexamethasone and oral steroids were initiated considering the diagnosis of TASS. Subsequently, the patient's VA increased, and the corneal edema decreased. We believe that the use of re-sterilized cannulas may have been the likely cause of TASS. Although DALK can be performed without interfering with the anterior chamber, one should keep in mind that TASS may occur in response to the solution used to hydrate the incision site and the air injected into the anterior chamber.


RESUMO Apresentamos o relato de uma paciente com 31 anos de idade, que desenvolveu síndrome tóxica do segmento anterior (TASS) após o procedimento de transplante lamelar anterior profundo (DALK). Ela apresentava ceratocone e, apesar de ter usado lentes de contato rígidas por muitos anos no olho esquerdo, apresentou deterioração da visão nesse olho que foi submetido a procedimento DALK. A acuidade visual (VA) era de conta dedos a três metros. O procedimento DALK de rotina foi realizado utilizando técnica de bolha grande (Big Bubble). A incisão de entrada da córnea foi hidratada ao final da cirurgia que foi terminada com a injeção de ar na câmara anterior. No primeiro dia de pós-operatório a VA era de percepção de movimentos da mão e a córnea estava edemaciada. Dexametasona tópica em alta dose e esteróides orais foram iniciadas ao se considerar o diagnóstico de TASS. Acreditamos que o uso de cânulas reesterilizadas podem ter sido a causa provável da TASS. A VA melhorou e o edema da córnea do diminuiu durante a evolução. Embora o procedimento DALK foi realizado sem interferir com câmara anterior, deve-se ter em mente que TASS pode ocorrer com a solução utilizada para hidratar o local da incisão e o ar injetado na câmara anterior.


Subject(s)
Humans , Female , Adult , Endophthalmitis/etiology , Corneal Transplantation/adverse effects , Anterior Eye Segment/pathology , Syndrome , Dexamethasone/therapeutic use , Visual Acuity , Endophthalmitis/pathology , Endophthalmitis/drug therapy , Edema , Keratoconus/surgery , Anti-Inflammatory Agents/therapeutic use
2.
An. bras. dermatol ; 91(5,supl.1): 122-124, Sept.-Oct. 2016. graf
Article in English | LILACS | ID: biblio-837945

ABSTRACT

Abstract A 40-year-old female patient with a 5-year history of systemic lupus erythematosus was referred to our policlinic with complaints of erythema, atrophy, and telangiectasia on the upper eyelids for 8 months. No associated mucocutaneous lesion was present. Biopsy taken by our ophthalmology department revealed discoid lupus erythematosus. Topical tacrolimus was augmented to the systemic therapeutic regimen of the patient, which consisted of continuous antimalarial treatment and intermittent corticosteroid drugs. We observed no remission in spite of the 6-month supervised therapy. Periorbital discoid lupus erythematosus is very unusual and should be considered in the differential diagnosis of erythematous lesions of the periorbital area..


Subject(s)
Humans , Female , Adult , Lupus Erythematosus, Discoid/pathology , Eyelid Diseases/pathology , Lupus Erythematosus, Systemic/pathology , Biopsy , Tacrolimus/therapeutic use , Adrenal Cortex Hormones/therapeutic use , Rare Diseases , Eyelids/pathology , Immunosuppressive Agents/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL